The International CCN Society

Log in | Register

Contact Us

President

Bernard Perbal

Bernard Perbal, D.Sc., LL.M

Previous Positions

  • Professor of Molecular Biology and Molecular Pathology
    University of PARIS 7- D. Diderot
  • Professor of Biotechnology
    University of PARIS VI - P. et M. Curie
  • Director of Research
    Centre National de la Recherche Scientifique (CNRS)
  • Associate Principal Scientist
    Open Research, L'Oréal USA
  • Senior Research Associate
    Scientific Direction, L'Oréal France

Societies

  • American Association for Cancer Research
  • American Association for the Advancement of Science
  • American Society for Microbiology, Molecular Biology Society
  • American Society for Virology
  • Founder of the International CCN Society

Awards

  • 1965 Laureate of the Concours Général de Sciences Naturelles (France)
  • 1990 Laureate of the French Académie des Sciences (Prix G. Rousseau)
  • 1992 Laureate of the Académie des Sciences (Grand Prix INSERM et Académie des Sciences )
  • 1992 Laureate of the French Ligue Nationale Contre le Cancer (Prix S. Dumonteil)
  • 2012 International CCN Society Award

Books and Reports

  • A Practical Guide to Molecular Cloning (Wiley,1988,1992)
  • Molecular Biology of Polyomaviruses and Herpes viruses (Wiley, 1982)
  • Clonage Moléculaire : Un guide Pratique (Vigot, 1989)
  • Encyclopedia of Molecular Biology (Wiley, 1999)
  • CCN Proteins: A New Family of Cell Growth and Differentiation Regulators (Editor, Imperial College Press, 2005)
  • CCN Proteins in Health and Disease (Editor, Springer, 2010)
  • La brevetabilité de l'innovation (79 pages in french) 2013
  • Focus on the patentability of computer programs (2014) J Cell Commun Signal.8(1):67-70

Editorial Board

  • Founder and former Editor in Chief of Methods in Molecular and Cellular Biology (Wiley, New York, 1998)
  • Founder and Editor in Chief of "Cell Communication and signaling" a former publication of BMC
  • Founder and Editor in Chief of "Journal of Cell Communication and signaling" published by Springer

Research Themes

I created the "Laboratoire d'Oncologie Virale et Moléculaire" in 1982. This laboratory was hosted successively at the "Institut Curie", the "Hôpital Saint-Antoine (INSERM)", and the "Université Paris 7 D. Diderot . Over the past 26 years, the research which was performed in the Laboratoire d'Oncologie Virale et Moléculaire has been funded by l' Association pour la Recherche contre le Cancer (ARC), La Fondation pour la Recherche Médicale (FRM), La ligue Nationale contre le Cancer (LNCC, Comités de Paris, du Cher et de l'Indre), l' Association Française contre les myopathies (AFM), La Fédération nationale des Groupements des Entreprises Françaises dans la Lutte contre le Cancer (GEFLUC), Le Centre National de la Recherche Scientifique (CNRS), L'Institut Curie, L'institut National de la Santé et de la Recherche Médicale (INSERM), Le Ministère de l'Education Nationale de la Recherche et de la Technologie (MENRT), l'Université Paris 7 D.Diderot, The European Union, and private donations.

Our studies were aimed at understanding :

  • the molecular basis for the Myeloblastosis Associated Virus (MAV) tumorigenic potential
  • the biochemical properties, mode of action and biological role of the CCN3(NOV) protein in normal and pathological conditions with a particular emphasis to the potential use of the CCN3 protein as a new tool for molecular medicine

The MAV strains usually induce osteopetrosis, lymphomas, and nephroblastomas in chicken (Perbal, Infect Agents Dis., 1995). Molecular cloning of a MAV strain inducing specifically nephroblastoma when injected in day-old chicken (Perbal, 1985, Soret et al. 1985) allowed to establish that MAV-induced nephroblastoma represent a unique animal model for the Wilms's tumor (Perbal Crit Rev Oncog., 1994). The identification of the MAV integration sites allowed us to identify several genes whose viral induced alteration is associated to cancer development (Li et al. 2006). Although early studies identified ccn3 as an integration site for MAV (Joliot et al. 1992) and suggested that it might be localized in a genomic hot spot for MAV integration, more recent results indicated that MAV did not integrate frequently in the vicinity of ccn3 (Li et al. 2006).

Studies performed in the laboratory (Perbal B. Mol Pathol. 2001, Perbal 2006) showed that the CCN3 protein may be acting either as a positive or negative regulator of cell growth in normal conditions. Disregulation of the ccn3 gene expression and abnormal production, processing or localization of the CCN3 protein is associated to malignancy in several tumor cases. Studies that we have performed established that CCN3 detection in tumor samples is associated to a favorable outcome in several types of tumors. In other cases, expression of ccn3 is associated to metastatic potentiality of the tumor cells (Planque and Perbal, Cancer Cell Int. 2003, Perbal, Expert Rev Mol Diagn. 2003). The value of CCN3 as a prognostic marker has been established in the case of osteosarcomas (Perbal et al. 2008) and melanomas (Vallacchi et al. 2008). The level of circulating CCN3 protein is also being used as a marker of pathological condition in several cases. Methods allowing quantitation of CCN3 in biological fluids and its use as a tool for molecular medicine are being developed. We have already established that the expression of ccn3 is reducing the tumorigenic potential of glioblastomas, choriocarcinomas, Ewing's tumors and melanomas. These observations set the stage for developing protocols for genetic therapy of these tumors.

Studies performed in the laboratory also aimed at identifying the proteins and ligands which interact with CCN3 and allow it to play its regulatory role in the control of cell attachement, spreading, proliferation and differentiation. Purification of the CCN3 protein has allowed us to undertake structural and functional studies which have already permitted the identification of signaling pathways into which CCN3 is acting.

Over the past few years, we have identified biologically active truncated CCN3 proteins with different subcellular localization (Perbal 2004, Planque et al. 2006). Since the nuclear CCN3 proteins detected in cancer cells have been shown to regulate transcription, we have proposed a model in which a balanced production of secreted CCN3 protein with anti-proliferative activity and nuclear CCN3 protein with pro-proliferative and oncogenic activities is required for the control of normal proliferation and differentiation. Disruption of this balance is associated to cancer development.

Selected Recent Publications


Full list available on PubMed
  • Perbal A, Perbal B.
    The CCN family of proteins: a 25th anniversary picture. J Cell Commun Signal. 2016 Sep;10(3):177-190
  • Yeger H, Perbal B.
    CCN family of proteins: critical modulators of the tumor cell microenvironment.
    J Cell Commun Signal. 2016 Sep;10(3):229-240.
  • Zhang C, van der Voort D, Shi H, Zhang R, Qing Y, Hiraoka S, Takemoto M, Yokote K, Moxon JV, Norman P, Rittié L, Kuivaniemi H, Atkins GB, Gerson SL, Shi GP, Golledge J, Dong N, Perbal B, Prosdocimo DA, Lin Z.
    Matricellular protein CCN3 mitigates abdominal aortic aneurysm.
    J Clin Invest. 2016 May 2;126(5):2012.
  • Perbal B, Lau L, Lyons K, Kubota S, Yeger H, Fisher G.
    Report on the 8th international workshop on the CCN family of genes - Nice November 3-8, 2015.
    J Cell Commun Signal. 2016 Mar;10(1):77-86.
  • Perbal B
    Tests génétiques en accès libre : Danger ou opportunité ?
    Le petit juriste Juillet-Août 2015
  • Perbal B
    Pour une liberté surveillée des tests génétiques
    Petites affiches Lextenso 8-9 Septembre 2015 N° 179-180
  • Perbal B.
    What kind of a life for a scientific journal?
    J Cell Commun Signal. 2015 Sep;9(3):201-6.
  • Perbal B, Perbal A
    Liberté, liberté chérie
    J Cell Commun Signal. 2015 Mar;9(1):1-4.
  • Perbal B
    Communication is the key. : Part 2 : Direct to consumer genetics in our future daily life ?
    J Cell Commun Signal. 2014 Dec;8(4):275-87
  • Perbal B
    7th International Workshop on the CCN family of genes: Nice to be in Nice
    J Cell Commun Signal. 2013 Aug;7(3):165-7.
  • Paradis R, Lazar N, Antinozzi P, Perbal B, Buteau J.
    Nov/Ccn3, a novel transcritional target to FoxO1, impairs pancreatic beta-cell function.
    PLoS One 2013 May;8(5):e64957.
  • Perbal B
    CCN Proteins : A Centralized Communication System.
    J Cell Commun Signal. 2013 Aug;7(3):169-77.
  • Abd El Kader T, Kubota S, Janune D, Nishida T, Hattori T, Aoyama E, Perbal B, Kuboki T, Takigawa M.
    Anti-fibrotic effect of CCN3 accompanied by altered gene expression profile of the CCN family.
    J Cell Commun Signal. 2013 Aug;7(1):11-8.
  • Perbal B
    Flaws in the peer-reviewing process : a critical look at a recent paper studying the role of CCN3 in renal cell carcinoma.
    J Cell Commun Signal. 2012 Aug;6(3):181-4.
  • van Roeyen CR, Boor P, Borkham-Kamphorst E, Rong S, Kunter U, Martin IV, Kaitovic A, Fleckenstein S, Perbal B, Trautwein C, Weiskirchen R, Ostendorf T, Floege J.
    A novel, dual role of CCN3 in experimental glomerulonephritis: pro-angiogenic and antimesangioproliferative effects.
    Am J Pathol. 2012 May;180(5):1979-90.
  • Perbal B
    CCN3: the-pain-killer inside me.
    J Cell Commun Signal. 2012 Jun;6(2):117-20. Epub 2012 Mar 30.
  • Janune D, Kubota S, Nishida T, Kawaki H, Perbal B, Iida S, Takigawa M.
    Novel effects of CCN3 that may direct the differentiation of chondrocytes.
    FEBS Lett. 2011 Aug 23. [Epub ahead of print]
  • McCallum L, Lu W, Price S, Lazar N, Perbal B, Irvine AE.
    CCN3 suppresses mitogenic signalling and reinstates growth control mechanisms in Chronic Myeloid Leukaemia.
    J Cell Commun Signal. 2011 Jul 20. [Epub ahead of print]
  • Kawaki H, Kubota S, Suzuki A, Suzuki M, Kohsaka K, Hoshi K, Fujii T, Lazar N, Ohgawara T, Maeda T, Perbal B, Takano-Yamamoto T, Takigawa M.
    Differential roles of CCN family proteins during osteoblast differentiation: Involvement of Smad and MAPK signaling pathways.
    Bone. 2011 Jul 7. [Epub ahead of print]
  • Suresh S, McCallum L, Lu W, Lazar N, Perbal B, Irvine AE.
    MicroRNAs 130a/b are regulated by BCR-ABL and downregulate expression of CCN3 in CML.
    J Cell Commun Signal. 2011 Aug;5(3):183-91. Epub 2011 Jun 3.
  • Tran CM, Smith HE, Symes A, Rittié L, Perbal B, Shapiro IM, Risbud MV.
    TGFβ controls CCN3 expression in nucleus pulposus cells of the intervertebral disc.
    TGFβ controls CCN3 expression in nucleus pulposus cells of the intervertebral disc.
  • Ouellet V, Tiedemann K, Mourskaia A, Fong JE, Tran-Thanh D, Amir E, Clemons M, Perbal B, Komarova SV, Siegel P.
    CCN3 impairs osteoblast and stimulates osteoclast differentiation to favor breast cancer metastasis to bone
    American Journal of Pahtology 2011 in press
  • Rittié L,Perbal B,Castellot JJ, Orringer JS, Voorhees JJ, Fisher GJ
    Spatial-temporal modulation of CCN proteins during wound healing in human skin in vivo
    J Cell Commun Signal. 2011 in press
    DOI: 10.1007/s12079-010-0114-y
  • Lin Z, Natesan V, Shi H, Hamik A, Kawanami D, Hao C, Mahabaleshwar GH, Wang W, Jin ZG, Atkins GB, Firth SM, Rittié L, Perbal B, Jain MK.
    A novel role of CCN3 in regulating endothelial inflammation.
    J Cell Commun Signal. 2010 Oct;4(3):141-53. Epub 2010 Aug 11.PMID: ‪
  • Riser BL, Najmabadi F, Perbal B, Rambow JA, Riser ML, Sukowski E, Yeger H, Riser SC, Peterson DR.
    CCN3/CCN2 regulation and the fibrosis of diabetic renal disease.
    J Cell Commun Signal. 2010 Mar;4(1):39-50. Epub 2010 Feb 9.PMID: 20195391 ‪
  • Lemaire R, Farina G, Bayle J, Dimarzio M, Pendergrass SA, Milano A, Perbal B, Whitfield ML, Lafyatis R.
    Antagonistic effect of the matricellular signaling protein CCN3 on TGF-beta- and Wnt-mediated fibrillinogenesis in systemic sclerosis and Marfan syndrome.
    J Invest Dermatol. 2010 Jun;130(6):1514-23. Epub 2010 Feb 25. Erratum in: J Invest Dermatol. 2010 Oct;130(10):2517. Perbal, Bernard [added]. PMID: 20182440 ‪
  • Shimoyama T, Hiraoka S, Takemoto M, Koshizaka M, Tokuyama H, Tokuyama T, Watanabe A, Fujimoto M, Kawamura H, Sato S, Tsurutani Y, Saito Y, Perbal B, Koseki H, Yokote K.‪
    ‬CCN3 inhibits neointimal hyperplasia through modulation of smooth muscle cell growth and migration. ‪
    ‬Arterioscler Thromb Vasc Biol. 2010 Apr;30(4):675-82. Epub 2010 Feb 5. ‪
  • Pasmant E, Ortonne N, Rittié L, Laurendeau I, Lévy P, Lazar V, Parfait B, Leroy K, Dessen P, Valeyrie-Allanore L, Perbal B, Wolkenstein P, Vidaud M, Vidaud D, Bièche I. ‪
    ‬Differential expression of CCN1/CYR61, CCN3/NOV, CCN4/WISP1, and CCN5/WISP2 in neurofibromatosis type 1 tumorigenesis. ‪
    ‬J Neuropathol Exp Neurol. 2010 Jan;69(1):60-9. ‪
  • Sin WC, Tse M, Planque N, Perbal B, Lampe PD, Naus CC. ‪
    ‬Matricellular protein CCN3 (NOV) regulates actin cytoskeleton reorganization. ‪
    ‬J Biol Chem. 2009 Oct 23;284(43):29935-44. Epub 2009 Aug 25.
  • Perbal B, Lazar N, Zambelli D, Lopez-Guerrero JA, Llombart-Bosch A, Scotlandi K, Picci P. ‪
    ‬Prognostic relevance of CCN3 in Ewing sarcoma. ‪
    ‬Hum Pathol. 2009 Oct;40(10):1479-86. Epub 2009 Aug 19. ‪
  • Tong Z, Chen R, Alt DS, Kemper S, Perbal B, Brigstock DR. ‪
    ‬Susceptibility to liver fibrosis in mice expressing a connective tissue growth factor transgene in hepatocytes. ‪
    ‬Hepatology. 2009 Sep;50(3):939-47.
  • ‬ McCallum L, Lu W, Price S, Lazar N, Perbal B, Irvine AE. ‪
    ‬CCN3: a key growth regulator in Chronic Myeloid Leukaemia. ‪
    ‬J Cell Commun Signal. 2009 Jun;3(2):115-24. Epub 2009 Jul 22. ‪
  • Perbal B. ‪
    ‬Alternative splicing of CCN mRNAs .... it has been upon us. ‪
    ‬J Cell Commun Signal. 2009 Jun;3(2):153-7. Epub 2009 Apr 28.
  • Riser BL, Najmabadi F, Perbal B, Peterson DR, Rambow JA, Riser ML, Sukowski E, Yeger H, Riser SC. ‪
    ‬CCN3 (NOV) is a negative regulator of CCN2 (CTGF) and a novel endogenous inhibitor of the fibrotic pathway in an in vitro model of renal disease. ‪
    ‬Am J Pathol. 2009 May;174(5):1725-34. Epub 2009 Apr 9.
  • Irvine AE, Perbal B, Yeger H. ‪
    ‬Report on the fifth international workshop on the CCN family of genes. ‪
    ‬J Cell Commun Signal. 2008 Dec;2(3-4):95-100. Epub 2009 Jan 21.
  • ‬ Holbourn KP, Acharya KR, Perbal B. ‪
    ‬The CCN family of proteins: structure-function relationships. ‪
    ‬Trends Biochem Sci. 2008 Oct;33(10):461-73. Epub 2008 Sep 11. ‪
  • ‬ Perbal B. ‪
    ‬CCN3: Doctor Jekyll and Mister Hyde. ‪
    ‬J Cell Commun Signal. 2008 Jun;2(1-2):3-7. Epub 2008 Sep 12.
  • Rittié L, Perbal B. ‪
    ‬Enzymes used in molecular biology: a useful guide. ‪
    ‬J Cell Commun Signal. 2008 Jun;2(1-2):25-45. Epub 2008 Sep 3‪
  • ‬ Kawaki H, Kubota S, Suzuki A, Lazar N, Yamada T, Matsumura T, Ohgawara T, Maeda T, Perbal B, Lyons KM, Takigawa M. ‪
    ‬Cooperative regulation of chondrocyte differentiation by CCN2 and CCN3 shown by a comprehensive analysis of the CCN family proteins in cartilage. ‪
    ‬J Bone Miner Res. 2008 Nov;23(11):1751-64. ‪
  • Yeger H, Perbal B.
    The CCN family of genes: a perspective on CCN biology and therapeutic potential.
    J Cell Commun Signal. 2008 Jun 21. [Epub ahead of print]
  • Perbal B.
    Avian Myeoloblastosis Virus (AMV) : only one side of the coin.
    Retrovirology. 2008 Jun 16;5(1):49. [Epub ahead of print]
  • Perbal B.
    CCN3-mutant mice are distinct from CCN3-null mice.
    J Cell Commun Signal. 2008 Jun 4. [Epub ahead of print]
  • Kawaki H , Kubota S, Suzuki A, Lazar N, Yamada T, Matsumura T, Ohgawara T, Maeda T, Perbal B, Lyons K, Takigawa M.
    Cooperative regulation of chondrocyte differentiation by CCN2 and CCN3 revealed by a comprehensive analysis of the CCN family proteins in cartilage
    J. Bone Miner. Res. 2008 ;
  • Katsuki Y, Sakamoto K, Minamizato T, Makino H, Umezawa A, Ikeda MA, Perbal B, Amagasa T, Yamaguchi A, Katsube K.
    Inhibitory effect of CT domain of CCN3/NOV on proliferation and differentiation of osteogenic mesenchymal stem cells, Kusa-A1.
    Biochem Biophys Res Commun. 2008 Apr 11;368(3):808-14. Epub 2008 Feb 12.
  • Perbal B, Zuntini M, Zambelli D, Serra M, Sciandra M, Cantiani L, Lucarelli E, Picci P, Scotlandi K.
    Prognostic value of CCN3 in osteosarcoma.
    Clin Cancer Res. 2008 Feb 1;14(3):701-9.
  • Vallacchi V, Daniotti M, Ratti F, Di Stasi D, Deho P, De Filippo A, Tragni G, Balsari A, Carbone A, Rivoltini L, Parmiani G, Lazar N, Perbal B, Rodolfo M.
    CCN3/nephroblastoma overexpressed matricellular protein regulates integrin expression, adhesion, and dissemination in melanoma.
    Cancer Res. 2008 Feb 1;68(3):715-23. Erratum in: Cancer Res. 2008 Mar 15;68(6):2051.
  • Subramaniam MM, Lazar N, Navarro S, Perbal B, Llombart-Bosch A.
    Expression of CCN3 protein in human Wilms' tumors: immunohistochemical detection of CCN3 variants using domain-specific antibodies.
    Virchows Arch. 2008 Jan;452(1):33-9. Epub 2007 Dec 8.
  • Kubota S, Yeger H, Perbal B, Takigawa M.
    Report on the fourth international workshop on the CCN family of genes.
    J Cell Commun Signal. 2007 Jun;1(1):59-65. Epub 2007 Apr 6.
  • Perbal A, Perbal B.
    CCN proteins, microenvironment, communication and signaling: why did we need a new journal?
    J Cell Commun Signal. 2007 Jun;1(1):1-3. Epub 2007 May 25.
  • Lazar N, Manara C, Navarro S, Bleau A-M, Llombart-Bosch A, Scotlandi K, Planque N, Perbal B.
    Domain-specific CCN3 antibodies as unique tools for structural and functional studies
    J. Cell Commun Signal. 2007 Sep;1(2):91-102. Epub 2007 Sep 8.
  • Fukunaga-Kalabis M, Martinez G, Telson SM, Liu ZJ, Balint K, Juhasz I, Elder DE, Perbal B, Herlyn M.
    Downregulation of CCN3 expression as a potential mechanism for melanoma progression.
    Oncogene. 2008 Apr 17;27(18):2552-60. Epub 2007 Oct 29.
  • van Roeyen CR, Eitner F, Scholl T, Boor P, Kunter U, Planque N, Grone HJ, Bleau AM, Perbal B, Ostendorf T, Floege J.
    CCN3 is a novel endogenous PDGF-regulated inhibitor of glomerular cell proliferation.
    Kidney Int. 2007 Oct 3; [Epub ahead of print]
  • Bleau AM, Planque N, Lazar N, Zambelli D, Ori A, Quan T, Fisher G, Scotlandi K, Perbal B.
    Antiproliferative activity of CCN3: Involvement of the C-terminal module and post-translational regulation.
    J Cell Biochem. 2007 Mar 5; [Epub ahead of print]
  • Minamizato T, Sakamoto K, Liu T, Kokubo H, Katsube KI, Perbal B, Nakamura S, Yamaguchi A.
    CCN3/NOV inhibits BMP-2-induced osteoblast differentiation by interacting with BMP and Notch signaling pathways.
    Biochem Biophys Res Commun. 2007 Mar 9;354(2):567-573. Epub 2007 Jan 16.
  • Perbal B.
    The CCN3 protein and cancer.
    Adv Exp Med Biol. 2006;587:23-40. Review.
  • Fukunaga-Kalabis M, Martinez G, Liu ZJ, Kalabis J, Mrass P, Weninger W, Firth SM, Planque N, Perbal B, Herlyn M.
    CCN3 controls 3D spatial localization of melanocytes in the human skin through DDR1.
    J Cell Biol. 2006 Nov 20;175(4):563-9. Epub 2006 Nov 13.
  • Yan X, Baxter RC, Perbal B, Firth SM.
    The aminoterminal insulin-like growth factor (IGF) binding domain of IGF binding protein-3 cannot be functionally substituted by the structurally homologous domain of CCN3.
    Endocrinology. 2006 Nov;147(11):5268-74. Epub 2006 Aug 24.
  • Perbal B.
    New insight into CCN3 interactions - Nuclear CCN3 : fact or fantasy?
    Cell Commun Signal. 2006 Aug 8;4:6.
  • McCallum L, Price S, Planque N, Perbal B, Pierce A, Whetton AD, Irvine AE.
    A novel mechanism for BCR-ABL action: stimulated secretion of CCN3 is involved in growth and differentiation regulation.
    Blood. 2006 Sep 1;108(5):1716-23. Epub 2006 May 2.
  • Planque N, Long Li C, Saule S, Bleau AM, Perbal B.
    Nuclear addressing provides a clue for the transforming activity of amino-truncated CCN3 proteins.
    J Cell Biochem. 2006 Sep 1;99(1):105-16.
  • Perbal B.
    NOV story: the way to CCN3.
    Cell Commun Signal. 2006 Feb 20;4:3.
  • Li CL, Coullin P, Bernheim A, Joliot V, Auffray C, Zoroob R, Perbal B.
    Integration of Myeloblastosis Associated Virus proviral sequences occurs in the vicinity of genes encoding signaling proteins and regulators of cell proliferation.
    Cell Commun Signal. 2006 Jan 10;4:1.
  • Brigstock D, Lau L, Perbal B.
    Report and abstracts of the 3rd International Workshop on the CCN Family of
    Genes. St Malo, France, 20-23 October 2004.
    J Clin Pathol. 2005 May;58(5):463-78.
  • Benini S, Perbal B, Zambelli D, Colombo MP, Manara MC, Serra M, Parenza M, Martinez V, Picci P, Scotlandi K.
    In Ewing's sarcoma CCN3(NOV) inhibits proliferation while promoting migration and invasion of the same cell type.
    Oncogene. 2005 Jun 23;24(27):4349-61.
  • Bleau AM, Planque N, Perbal B.
    CCN proteins and cancer: two to tango.
    Front Biosci. 2005 May 1;10:998-1009.
  • Kyurkchiev S, Yeger H, Bleau AM, Perbal B.
    Potential cellular conformations of the CCN3(NOV) protein.
    Cell Commun Signal. 2004 Sep 10;2(1):9.
  • Fu CT, Bechberger JF, Ozog MA, Perbal B, Naus CC.
    CCN3 (NOV) interacts with connexin43 in C6 glioma cells: possible mechanism of connexin-mediated growth suppression.
    J Biol Chem. 2004 Aug 27;279(35):36943-50. Epub 2004 Jun 21.
  • Gellhaus A, Dong X, Propson S, Maass K, Klein-Hitpass L, Kibschull M, Traub O, Willecke K, Perbal B, Lye SJ, Winterhager E.
    Connexin43 interacts with NOV: a possible mechanism for negative regulation of cell growth in choriocarcinoma cells.
    J Biol Chem. 2004 Aug 27;279(35):36931-42. Epub 2004 Jun 4.
  • Katsube K, Chuai ML, Liu YC, Kabasawa Y, Takagi M, Perbal B, Sakamoto K.
    The expression of chicken NOV, a member of the CCN gene family, in early stage development.
    Brain Res Gene Expr Patterns. 2001 Aug;1(1):61-5.
  • Perbal B.
    CCN proteins : multifunctional signalling regulators.
    Lancet 2004 Jan;363(9) :62-64
  • Yu C, Le AT, Yeger H, Perbal B, Alman BA.
    NOV (CCN3) regulation in the growth plate and CCN family member expression in cartilage neoplasia.
    J Pathol. 2003 Dec;201(4):609-15.
  • Perbal B.
    Communication is the key.
    Cell Commun Signal. 2003 Oct 27;1(1):3.
  • Lombet A, Planque N, Bleau AM, Li CL, Perbal B.
    CCN3 and calcium signaling.
    Cell Commun Signal. 2003 Aug 15;1(1):1.
  • Perbal B.
    The CCN3 (NOV) cell growth regulator: a new tool for molecular medicine.
    Expert Rev Mol Diagn. 2003 Sep;3(5):597-604.
  • Planque N, Perbal B.
    A structural approach to the role of CCN (CYR61/CTGF/NOV) proteins in tumourigenesis.
    Cancer Cell Int. 2003 Aug 22;3(1):15.
  • Brigstock DR, Goldschmeding R, Katsube KI, Lam SC, Lau LF, Lyons K, Naus C, Perbal B, Riser B, Takigawa M, Yeger H.
    Proposal for a unified CCN nomenclature.
    Mol Pathol. 2003 Apr;56(2):127-8.
  • Perbal B, Brigstock DR, Lau LF.
    Report on the second international workshop on the CCN family of genes.
    Mol Pathol. 2003 Apr;56(2):80-5.
  • Coullin P, Li CL, Ziercher L, Auffray C, Bernheim A, Zoorob R, Perbal B.
    Assignment of the chicken NOV gene (alias CCN3) to chromosome 2q34-->q36:
    Conserved and compared synteny between avian, mouse and human.
    Cytogenet Genome Res. 2002;97(1-2):140C.
  • Li CL, Martinez V, He B, Lombet A, Perbal B.
    A role for CCN3 (NOV) in calcium signalling.
    Mol Pathol. 2002 Aug;55(4):250-61.
  • Sakamoto K, Yamaguchi S, Ando R, Miyawaki A, Kabasawa Y, Takagi M, Li CL, Perbal B, Katsube K.
    The nephroblastoma overexpressed gene (NOV/ccn3) protein associates with Notch1 extracellular domain and inhibits myoblast differentiation via Notch signaling pathway.
    J Biol Chem. 2002 Aug 16;277(33):29399-405. Epub 2002 Jun 05.
  • Manara MC, Perbal B, Benini S, Strammiello R, Cerisano V, Perdichizzi S, Serra M, Astolfi A, Bertoni F, Alami J, Yeger H, Picci P, Scotlandi K.
    The expression of ccn3(nov) gene in musculoskeletal tumors.
    Am J Pathol. 2002 Mar;160(3):849-59.
  • Perbal B.
    Les protéines CCN : quand multimodulaire rime avec multifonctionnel.
    Médecine-Sciences. 2002 Jun;18 :745-56
  • Thomopoulos GN, Kyurkchiev S, Perbal B.
    Immunocytochemical localization of NOVH protein and ultrastructural characteristics of NCI-H295R cells.
    J Submicrosc Cytol Pathol. 2001 Jul;33(3):251-60.
  • Glukhova L, Angevin E, Lavialle C, Cadot B, Terrier-Lacombe MJ, Perbal B, Bernheim A, Goguel AF.
    Patterns of specific genomic alterations associated with poor prognosis in high-grade renal cell carcinomas.
    Cancer Genet Cytogenet. 2001 Oct 15;130(2):105-10.
  • Gupta N, Wang H, McLeod TL, Naus CC, Kyurkchiev S, Advani S, Yu J, Perbal B, Weichselbaum RR.
    Inhibition of glioma cell growth and tumorigenic potential by CCN3 (NOV).
    Mol Pathol. 2001 Oct;54(5):293-9.